BACKGROUND: The importance of Th2-type lymphocyte function in asthmatic airway inflammation is well recognized, but less is known about the factors which regulate the function of these lymphocytes in asthma. The macrophage-derived cytokine, interleukin (IL)-15 has a number of T cell regulatory properties which might be of relevance to asthma and its treatment. OBJECTIVE: The aims were to identify and quantify the T cell regulatory cytokine IL-15 in induced sputum samples from asthmatic patients, in comparison with IL-13, and to relate the levels of these cytokines to treatment with inhaled steroids. METHODS: Induced sputum was collected from 16 asthmatics (eight steroid and eight non-steroid treated) and eight normal controls. IL-15 and IL-13 levels were measured by enzyme-linked immunoassay (ELISA) in sputum. IL-15 levels were also measured in sputum cell culture supernatants and localized to specific sputum cells by immuno-cytochemistry. RESULTS: IL-15 levels were increased and IL-13 levels were decreased in sputum fluid from steroid-treated compared with non-steroid-treated asthmatics. IL-15 was localized specifically to macrophages and the proportion of these cells expressing IL-15 correlated with sputum fluid IL-15 and IL-15 levels in cell culture supernatants, and all were higher in the steroid-treated asthmatics. CONCLUSION: IL-15 and IL-13 production appears to be reciprocally regulated by steroid therapy in asthma patients. The steroid-associated increase in IL-15 may regulate a fundamental shift away from an inflammatory Th2-type environment in asthma and may be an essential component of the cytokine modulation underlying the therapeutic benefit of corticosteroids in this condition.
BACKGROUND: The importance of Th2-type lymphocyte function in asthmatic airway inflammation is well recognized, but less is known about the factors which regulate the function of these lymphocytes in asthma. The macrophage-derived cytokine, interleukin (IL)-15 has a number of T cell regulatory properties which might be of relevance to asthma and its treatment. OBJECTIVE: The aims were to identify and quantify the T cell regulatory cytokine IL-15 in induced sputum samples from asthmatic patients, in comparison with IL-13, and to relate the levels of these cytokines to treatment with inhaled steroids. METHODS: Induced sputum was collected from 16 asthmatics (eight steroid and eight non-steroid treated) and eight normal controls. IL-15 and IL-13 levels were measured by enzyme-linked immunoassay (ELISA) in sputum. IL-15 levels were also measured in sputum cell culture supernatants and localized to specific sputum cells by immuno-cytochemistry. RESULTS:IL-15 levels were increased and IL-13 levels were decreased in sputum fluid from steroid-treated compared with non-steroid-treated asthmatics. IL-15 was localized specifically to macrophages and the proportion of these cells expressing IL-15 correlated with sputum fluid IL-15 and IL-15 levels in cell culture supernatants, and all were higher in the steroid-treated asthmatics. CONCLUSION:IL-15 and IL-13 production appears to be reciprocally regulated by steroid therapy in asthmapatients. The steroid-associated increase in IL-15 may regulate a fundamental shift away from an inflammatory Th2-type environment in asthma and may be an essential component of the cytokine modulation underlying the therapeutic benefit of corticosteroids in this condition.
Authors: C B Mathias; C M Schramm; L A Guernsey; C A Wu; S H Polukort; J Rovatti; J Ser-Dolansky; E Secor; S S Schneider; R S Thrall; H L Aguila Journal: Clin Exp Allergy Date: 2017-02-07 Impact factor: 5.018
Authors: Mateusz Jonakowski; Jan Zioło; Marcelina Koćwin; Marcelina Przemęcka; Łukasz Mokros; Michał Panek; Janusz Szemraj; Piotr Kuna Journal: Exp Ther Med Date: 2017-09-05 Impact factor: 2.447
Authors: Shironjit K Saha; Mike A Berry; Deborah Parker; Salman Siddiqui; Angela Morgan; Richard May; Phillip Monk; Peter Bradding; Andrew J Wardlaw; Ian D Pavord; Christopher E Brightling Journal: J Allergy Clin Immunol Date: 2008-03 Impact factor: 10.793
Authors: R D May; P D Monk; E S Cohen; D Manuel; F Dempsey; N H E Davis; A J Dodd; D J Corkill; J Woods; C Joberty-Candotti; L A Conroy; F Koentgen; E C Martin; R Wilson; N Brennan; J Powell; I K Anderson Journal: Br J Pharmacol Date: 2012-05 Impact factor: 8.739
Authors: Salman Siddiqui; Glenn Cruse; Susan McKenna; William Monteiro; Vijay Mistry; Andrew Wardlaw; Christopher Brightling Journal: BMC Pulm Med Date: 2009-07-14 Impact factor: 3.317